GlassScriptPhysician profile
Patricia Mcclerklin
NPI 1154428100
$32,676.73
in general payments reported to CMS, 2019-2025
45 companies · $3,968 in 2025
The $3,968 reported for 2025 was more than what 88% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $10K · 2020: $2,164 · 2021: $3,313 · 2022: $4,161 · 2023: $4,593 · 2024: $4,362 · 2025: $3,968.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $13K · Education: $344.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $12,578.81 |
| Education | $343.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $6,439.47 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $3,129.70 | 2019-2025 | |
| Abbvie INC. | $2,842.98 | 2019-2025 | |
| Janssen Biotech, INC. | $1,875.68 | 2019-2025 | Tremfya, Simponi, Simponi Aria |
| Genzyme Corporation | $1,694.89 | 2019-2025 | |
| Ucb, INC. | $1,635.82 | 2019-2025 | Bimzelx, Cimzia |
| E.R. Squibb & Sons, L.L.C. | $1,173.82 | 2022-2024 | Sotyktu |
| Medimetriks Pharmaceuticals, INC. | $1,038.83 | 2019-2023 | Clodan |
| Amgen INC. | $1,025.54 | 2019-2025 | Otezla, Otezla, Enbrel |
| Leo Pharma INC. | $998.80 | 2019-2025 | Adbry, Anzupgo, Spevigo |
| Paratek Pharmaceuticals, INC. | $976.28 | 2021-2025 | Nuzyra |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $963.45 | 2019-2025 | Siliq, Targretin, Cabtreo |
| Sun Pharmaceutical Industries INC. | $955.38 | 2019-2025 | Winlevi, Absorica Ld, Ilumya |
| Lilly USA, LLC | $897.97 | 2019-2025 | Taltz, Olumiant, Ebglyss |
| Almirall LLC | $875.75 | 2019-2025 | Klisyri, Seysara |
Show all 45 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patricia Mcclerklin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.